Questcor Pharmaceuticals, Inc. (Headquarters) Announces Presentation Of Data On H.P. Acthar Gel At American Epilepsy Society Annual Meeting

UNION CITY, Calif.--(BUSINESS WIRE)--Questcor Pharmaceuticals, Inc. (AMEX:QSC) today announced that data from six posters related to the company's marketed product H.P. Acthar® Gel (repository corticotropin injection) will be presented at the annual meeting of the American Epilepsy Society (AES) December 1-5 in San Diego, California. These six posters discuss use of H.P. Acthar Gel in the treatment of Infantile Spasms, a life-threatening form of childhood epilepsy. Questcor is seeking U.S. Food and Drug Administration (FDA) approval of H.P. Acthar Gel, a natural adrenocorticotropic hormone (ACTH), for the treatment of Infantile Spasms. H.P. Acthar Gel is currently approved for a number of diseases and disorders, including the treatment of Multiple Sclerosis exacerbations.